GAD2 and type 1 diabetes mellitus: GAD65 is a commonly targeted autoantigen in type 1 diabetes, it was combined with alum as an adjuvant and subcutaneously administered to recent-onset patients with type 1 diabetes with the aim of shifting the autoimmune response from a TH1 to a TH2 response.